Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas - An International Collaborative StudyDaly, Adrian ; ; Petrossians, Patrick et alin Journal of Clinical Endocrinology and Metabolism (2010), 95(11), Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features ... [more ▼] Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. [less ▲] Detailed reference viewed: 66 (33 ULg) Mutations AIP chez les jeunes patients en dessous de 30 ans avec adénome hypophysaire agressifBeckers, Albert ; ; et alin Annales d'Endocrinologie (2010, September), 71(5), 397 Detailed reference viewed: 18 (3 ULg) Mutations AIP chez les jeunes patients en-dessous de 30 ans avec adénome hypophysaire agressifBeckers, Albert ; ; et alin 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September) Detailed reference viewed: 22 (4 ULg) High Prevalence of AIP Gene Mutations Following Focussed Screening in Young Patients with Sporadic Pituitary Macroadenomas; ; Daly, Adrian et alin European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September) Detailed reference viewed: 13 (3 ULg) High Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas; Daly, Adrian ; et alin 52 Symposium der Deutschen Gesellschaft für Endokrinologie (2009, March) Detailed reference viewed: 5 (0 ULg) An analysis of the role of cyclin dependant kinase inhibitor 1B (CDKN1B) gene mutations in 86 families with familial isolated pituitary adenomas (FIPA); Daly, Adrian ; Pujol, Julien et alin The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009) Detailed reference viewed: 21 (6 ULg) High Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas; Daly, Adrian ; et alin The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009) Detailed reference viewed: 20 (2 ULg) |
||